«观察等待»滤泡性淋巴瘤24个月内接受淋巴瘤治疗与较差结局相关:一项多中心分析
该多中心回顾性研究纳入2008至2022年16个癌症中心的411例接受观察等待策略的滤泡性淋巴瘤患者,评估其至淋巴瘤治疗时间与无进展生存期。35%的患者在诊断后24个月内接受治疗,其5年无进展生存率显著低于24个月未治疗者(62.3% vs 89.5%)。多变量分析识别出5个独立预测因素并构建风险评分,有助于筛选可能从早期干预中获益的患者。
要点
- 35%的观察等待滤泡性淋巴瘤患者在诊断后24个月内接受治疗。
- 24个月内接受治疗者5年无进展生存率显著低于未治疗者(62.3% vs 89.5%)。
- 基于5个独立预测因素的多变量模型有助于筛查24个月内需治疗的患者。
核心结论
- 在初始接受观察等待策略的滤泡性淋巴瘤患者中,24个月内接受淋巴瘤治疗与较差结局相关。
- 该多变量模型有助于预测24个月内接受治疗,可能有助于识别早期干预治疗的候选者。
研究设计与样本
- 回顾性多中心分析,纳入2008至2022年16个癌症中心的411例接受观察等待策略的滤泡性淋巴瘤患者,评估至淋巴瘤治疗时间和无进展生存期。
主要发现
- 35%的观察等待滤泡性淋巴瘤患者在诊断后24个月内接受淋巴瘤治疗(TLT24)。
- TLT24患者的5年无进展生存率显著低于24个月时未治疗者(62.3% vs 89.5%)。
- 多变量分析识别出5个TLT24独立预测因素:III-IV期、β2微球蛋白≥3 mg/L、淋巴细胞与单核细胞比值<3.8、骨髓受累和脾肿大(超过脐线)。
- 该模型预测TLT24的AUC在训练队列为0.76(95% CI,0.70-0.82),在验证队列为0.76(95% CI,0.67-0.85)。
- 风险分组也与无进展生存期相关(p < 0.001)。
关键数值与推荐
- TLT24的独立预测因素包括III-IV期、β2微球蛋白≥3 mg/L、淋巴细胞与单核细胞比值<3.8、骨髓受累和脾肿大(超过脐线)。
- 模型预测TLT24的AUC:训练队列0.76(95% CI,0.70-0.82),验证队列0.76(95% CI,0.67-0.85)。
- 风险分组与无进展生存期相关(p < 0.001)。
临床怎么用
- 作者认为该多变量模型有助于筛查预测TLT24,可能有助于识别早期干预治疗的候选者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Some 'watch and wait' (W&W) FL patients suffer from rapid progression in a short term. Herein, we sought to identify these patients and also develop a risk score to screen them at diagnosis. Between 2008 and 2022, a total of 411 FL patients managed by the W&W strategy from 16 cancer centres were retrospectively enrolled in this study, and their time to lymphoma treatment (TLT) and progression-free survival (PFS) were evaluated. Thirty-five percent of W&W FL patients experienced TLT within 24 months (TLT24) after diagnosis. Their 5-year PFS rate was significantly lower than those without treatment at 24 months (62.3% vs. 89.5%). In multivariable analysis, five factors were identified as independent predictors of TLT24: stages III-IV, β2 microglobulin ≥3 mg/L, lymphocyte-to-monocyte ratio <3.8, bone marrow involvement and spleen enlargement (above umbilical line). Their AUCs for TLT24 were 0.76 (95% CI, 0.70-0.82) in the training cohort and 0.76 (95% CI, 0.67-0.85) in the validation cohort respectively. Risk groups were also associated with PFS (p < 0.001). In FL patients initially managed by W&W, TLT24 was associated with poor outcomes. This multivariable model helps screening for predicting TLT24, which may be useful to identify candidates for early interventional treatment.
引用
- Liu J, Gao F, Zhang T, et al. Time to lymphoma treatment within 24 months in 'watch and wait' follicular lymphoma is associated with inferior outcomes: A multicentre analysis. Br J Haematol. 2024. PMID: 39327747. doi:10.1111/bjh.19770
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。